Yeztugo (lenacapavir) is an HIV-1 capsid inhibitor that is administered every 6 months after an initial dosing regimen.

Stigma and lack of support hinder PrEP use among Black women; clinician bias and discrimination worsen disparities.

A new pre-exposure prophylaxis (PrEP) drug has shown promise as a once-monthly oral pill to help prevent HIV. PrEP plays a key part in reducing the number of new HIV infections by stopping the virus ...

Gilead's groundbreaking HIV prevention drug will soon be available at a fraction of its U.S. price in over 100 countries, ...

A new survey launched by Global Black Gay Men Connect is seeking responses from Black gay men and Black trans community ...

Please provide your email address to receive an email when new articles are posted on . Survey results showed that transgender women and transfeminine nonbinary people support OTC PrEP. Lauren ...

Patrick Sullivan, DVM, PhD, an infectious disease epidemiologist and professor of epidemiology at Emory University in Atlanta, Georgia, spoke about his recent analysis that revealed that modest ...

The HIV-prevention pill PrEP will now be covered under most insurance plans. Its name is short for pre-exposure prophylaxis. Supporters of the move to make it free to those who are insured call it a ...

Increased PrEP usage is linked to decreased HIV diagnosis rates, with a notable decline from 13.0 to 10.6 per 100,000 over a decade. State-level PrEP coverage significantly impacts HIV diagnosis rates ...

Nearly one in three gay and bisexual men who were diagnosed with HIV at UK sexual health clinics didn't meet the criteria for "high risk" that would signal to a clinician that they would be good ...

Funding cuts are affecting countries with high HIV rates by creating shortages of community health workers and data ...